- Trials with a EudraCT protocol (1,806)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,806 result(s) found for: PCR test.
Displaying page 1 of 91.
EudraCT Number: 2021-002894-24 | Sponsor Protocol Number: C4671006 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATI... | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005458-97 | Sponsor Protocol Number: VAC18193RSV3001 | Start Date*: 2021-10-28 |
Sponsor Name:Janssen Vaccines & Prevention B.V. | ||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years an... | ||
Medical condition: Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004905-15 | Sponsor Protocol Number: DNDi-FEX-12-CH | Start Date*: 2017-09-13 |
Sponsor Name:Drugs for Neglected Diseases initiative (DNDi) | ||
Full Title: Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease | ||
Medical condition: Chagas disease (CD) is a disease caused by Trypanosoma cruzi, ranking among the world’s most neglected diseases. There is significant associated morbidity and mortality, particularly in chronic ph... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005598-28 | Sponsor Protocol Number: ADG20PREV001 | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Adagio Therapeutics Inc | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE) | |||||||||||||
Medical condition: The prevention of symptomatic coronavirus (CoV) disease 2019 (COVID 19) in adults and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) BG (Completed) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001416-29 | Sponsor Protocol Number: PREDEXACOV | Start Date*: 2021-08-31 |
Sponsor Name:Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive | ||
Full Title: EARLY TREATMENT STRATEGY WITH HIGH-DOSE VERSUS STANDARD-DOSE DEXAMETHASONE IN PATIENTS WITH SARS-COV-2 PNEUMONIA (COVID-19). | ||
Medical condition: Adult patients with SARS-CoV-2 infection (COVID19) requiring hospital admission for pneumonia. Who present pcr ≥ 66 mg/L and ≤150 mg/L at inclusion or Pandemic score [13] on admission > 200 with pc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004611-50 | Sponsor Protocol Number: CCTU0228 | Start Date*: 2019-06-14 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in p... | ||
Medical condition: Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000568-28 | Sponsor Protocol Number: GO28888 | Start Date*: 2014-10-16 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A phase II randomized, double-blind study of neoadjuvant letrozole plus GDC-0032 versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer | |||||||||||||
Medical condition: WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) AT (Completed) CZ (Completed) PT (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004163-21 | Sponsor Protocol Number: A0661157 | Start Date*: 2015-04-06 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa | |||||||||||||
Medical condition: Malaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002546-20 | Sponsor Protocol Number: 104820 | Start Date*: 2006-11-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly ac... | ||
Medical condition: For active immunization of girls and women from 10 years of age onwards for the prevention of persistent human papillomavirus (HPV) infections and related clinical outcomes (cytological abnormaliti... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004137-21 | Sponsor Protocol Number: 78591.041.21 | Start Date*: 2021-10-28 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study | ||
Medical condition: respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000492-36 | Sponsor Protocol Number: HOPECOVID-19 | Start Date*: 2021-05-31 | |||||||||||
Sponsor Name:UCLouvain | |||||||||||||
Full Title: Home and Outpatients Precocious Eradication of COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004531-22 | Sponsor Protocol Number: MBA 1/2005 | Start Date*: 2006-05-02 |
Sponsor Name:Májbetegekért Alapítvány | ||
Full Title: Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 weeks of Combined Treatment of Patients Receiving Pegasys and Copegus who are Biochemical Responders but Virolo... | ||
Medical condition: Chronic hepatitis C virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001827-15 | Sponsor Protocol Number: CORTIVID | Start Date*: 2020-04-30 |
Sponsor Name:NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET | ||
Full Title: EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL | ||
Medical condition: CoVid-19 pneumonia in early inflammatory phase (stage II). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004906-14 | Sponsor Protocol Number: A0661201 | Start Date*: 2015-04-07 |
Sponsor Name:Pfizer Inc | ||
Full Title: An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithro... | ||
Medical condition: Asymptomatic Parasitemia | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-001417-21 | Sponsor Protocol Number: ITM202004 | Start Date*: 2020-04-12 | |||||||||||
Sponsor Name:Institute of Tropical Medicine | |||||||||||||
Full Title: An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001767-86 | Sponsor Protocol Number: COVIRL-002 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000757-21 | Sponsor Protocol Number: P04823 | Start Date*: 2006-08-15 |
Sponsor Name:AESCA Pharma GmbH | ||
Full Title: Study to evaluate Response Rates in CHC Patients genotype 1 with Insulin Resistance and to assess prolonged Treatment Duration in late virological Responders | ||
Medical condition: chronic hepatitis C, genotype 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-002723-16 | Sponsor Protocol Number: PREMIVER | Start Date*: 2018-04-20 |
Sponsor Name:Universitaetsklinikum Tuebingen | ||
Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial | ||
Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014.... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003194-33 | Sponsor Protocol Number: VAC18193RSV2002 | Start Date*: 2017-10-03 |
Sponsor Name:Janssen Vaccines and Prevention B.V. | ||
Full Title: An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infe... | ||
Medical condition: Prophylactic respiratory syncytial virus (RSV) vaccine. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
